yinuoxin zurletrectinib tablets solid tumor 4mg

Description

Indication & Scope

treats locally advanced or metastatic solid tumors harboring NTRK gene fusion in patients aged 12 years and older.

Mechanism: Next-generation highly selective tropomyosin receptor kinase inhibitor (TRKA/TRKB/TRKC and ROS1 inhibitor). It binds ATP-binding pocket of NTRK fusion-derived TRK oncoproteins, blocks downstream tumor proliferation signaling pathways and induces cancer cell apoptosis, with strong blood-brain barrier penetration for intracranial metastatic lesions.
Drug class: Oral small-molecule NTRK/ROS1 tyrosine kinase inhibitor / Pan-TRK anti-tumor targeted therapy.
Clinical use: First-line targeted therapy for unresectable NTRK fusion-positive solid tumors across multiple tissue origins; effective for patients with central nervous system metastasis resistant to first-generation TRK inhibitors.

Specification

Generic Name	Zurletrectinib Tablets
Brand Name	YiNuoXin
Ingredient	Zurletrectinib
Dosage Form	Tablets
Package	4mg*60 tablets/box
Conditions Treated	NTRK fusion-positive locally advanced or metastatic solid tumors
Taboos	Severe hypersensitivity to zurletrectinib or tablet excipients; patients with severe untreated hepatic impairment; pregnant or breastfeeding individuals
Place of origin	China
Prescription type	Prescription-only
Storage Conditions	Store sealed blister packs at controlled room temperature 10°C to 30°C, sealed to prevent moisture ingress
Manufacturer	Innocare Pharmaceutical, Ltd.
Registration Authority	National Medical Products Administration (NMPA), China
Approval number	H20250071
Approval Date	Dec 9, 2025
Shelf Life	24 months

How to use ?

Recommended Dose: Standard dose 100 mg oral twice daily, taken continuously until disease progression or intolerable toxicity occurs.

Time: Two equal doses administered at 12-hour intervals daily, with consistent food intake (low-fat meals recommended).

Instructions for use: Swallow whole tablet with water, do not split or crush; adjust dose downward for grade 3 or higher liver toxicities; perform baseline NTRK fusion genetic testing before treatment initiation.

Interaction: Strong CYP3A4 inhibitors increase systemic zurletrectinib exposure and toxicity risk; strong CYP3A4 inducers significantly reduce therapeutic plasma concentrations.

Side effects:

1. Common: mild fatigue, dizziness, nausea, diarrhea, elevated liver transaminases, myalgia.

2. Severe grade ≥3 adverse events: severe hepatotoxicity, sensory peripheral neuropathy, interstitial lung disease.

Important Notice

This product should be administered only by qualified healthcare professionals in accordance with the approved prescribing information and local clinical guidelines. Dosage and administration may vary depending on patient condition, indicatiaon, and regional regulatory requirements.

Packaging & Shipping

Packaging

Original manufacturer’s packaging with secure export carton. Customized export packaging is available upon request.

Shipping Methods

Express Courier (EMS, DHL, FedEx, UPS), Air Freight, and Sea Freight. Cold-chain transportation is available for products requiring temperature-controlled logistics.

Export Support